Wright Brings New Biologic To U.S. Ortho Space With Augment Approval
This article was originally published in The Gray Sheet
Executive Summary
The Augment biologic-based device was approved for use in ankle and hindfoot fusions after overcoming multiple regulatory challenges.
You may also be interested in...
Cervical Spine Bone Graft Gains FDA Go-Ahead
Cerapedics' i-Factor peptide-enhanced bone graft will be used to treat degenerative cervical disc disease, the first bone graft product PMA-approved for that indication, the company says.
Wright Medical Augments Ortho Extremities Biz With BioMimetic Purchase
Firm expects to gain PMA approval in 2013 for BioMimetic’s Augment bone graft as a replacement for autologous bone graft in foot and ankle fusion procedures. Deal includes $190 million down, and up to $190 million more in milestone payments.
EU Regulatory Assessors Get AI Boost In Reaching Scientific Decisions
The European Medicines Agency is training scientific staff working for the European medicines regulatory network in how to use a new AI-powered search engine that allows them to easily retrieve information on regulatory precedents.